4200 MARATHON BLVD., AUSTIN, TX
2026 Annual Meeting Results - Plus Therapeutics Stockholder Votes
Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Appointment of Dr. Eric J. Daniels as Chief Development Officer
Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
Announces Reverse Stock Split
Annual Report to Security Holders
Ronald A. Andrews Appointed to Plus Therapeutics Board of Directors
Q1
Q3
Q2
Notice of Late Filing for Quarterly Report
Amended Annual Report
FY 2024
RW
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Direct Registration System
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
S-1MEF
Correspondence
Submission Upload